Michael B. Hoffman - 18 Jan 2023 Form 4 Insider Report for Annovis Bio, Inc. (ANVS)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ANVS
Reported as of: 18 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Jan 2023, 16:38:36 UTC
Prior SEC filing: 05 Jan 2022
Next SEC filing: 11 Apr 2023
Source filing: View source filing
Reporting owner signature: /s/ Henry Hagopian III, Attorney-in-Fact for Michael Hoffman

Key filing fact

Michael B. Hoffman filed Form 4 for Annovis Bio, Inc. (ANVS) on 20 Jan 2023.

Key facts

This page summarizes Michael B. Hoffman's Form 4 filing for Annovis Bio, Inc. (ANVS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Jan 2023, 16:38.

Change

Previous filing in this sequence was filed on 05 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANVS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +6,820
Change %
Price: $0.000000
Shares after: 6,820
Date: 18 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,820
Exercise price: $13.17
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option shall vest in eight consecutive equal quarterly installments each on the 18th day of April, July, October and January of each year, commencing April 18, 2023, and continuing through January 18, 2025.